Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980 to Filter to 2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980

---

Search results

• Journal article
  Barba T, Kettner H, Radu C, Peill J, Roseman L, Nutt D, Erritzoe D, Carhart-Harris R, Cunha Bet al., 2024,

  Psychedelics and sexual functioning: a mixed-methods study

  , Scientific Reports, Vol: 14, ISSN: 2045-2322

  Do psychedelics affect sexual functioning postacutely? Anecdotal and qualitative evidence suggests they do, but this has never been formally tested. While sexual functioning and satisfaction are generally regarded as an important aspect of human wellbeing, sexual dysfunction is a common symptom of mental health disorders. It is also a common side effect of selective serotonin reuptake inhibitors (SSRIs), a first line treatment for depression. The aim of the present paper was to investigate the post-acute effects of psychedelics on self-reported sexual functioning, combining data from two independent studies, one large and naturalistic and the other a smaller but controlled clinical trial. Naturalistic use of psychedelics was associated with improvements in several facets of sexual functioning and satisfaction, including improved pleasure and communication during sex, satisfaction with one’s partner and physical appearance. Convergent results were found in a controlled trial of psilocybin therapy versus an SSRI, escitalopram, for depression. In this trial, patients treated with psilocybin reported positive changes in sexual functioning after treatment, while patients treated with escitalopram did not. Despite focusing on different populations and settings, this is the first research study to quantitively investigate the effects of psychedelics on sexual functioning. Results imply a potential positive effect on post-acute sexual functioning and highlight the need for more research on this.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Mediano PAM, Rosas FE, Timmermann C, Roseman L, Nutt DJ, Feilding A, Kaelen M, Kringelbach ML, Barrett AB, Seth AK, Muthukumaraswamy S, Bor D, Carhart-Harris RLet al., 2024,

  Effects of external stimulation on psychedelic state neurodynamics

  , ACS Chemical Neuroscience, Vol: 15, Pages: 462-471, ISSN: 1948-7193

  Recent findings have shown that psychedelics reliably enhance brain entropy (understood as neural signal diversity), and this effect has been associated with both acute and long-term psychological outcomes, such as personality changes. These findings are particularly intriguing, given that a decrease of brain entropy is a robust indicator of loss of consciousness (e.g., from wakefulness to sleep). However, little is known about how context impacts the entropy-enhancing effect of psychedelics, which carries important implications for how it can be exploited in, for example, psychedelic psychotherapy. This article investigates how brain entropy is modulated by stimulus manipulation during a psychedelic experience by studying participants under the effects of lysergic acid diethylamide (LSD) or placebo, either with gross state changes (eyes closed vs open) or different stimuli (no stimulus vs music vs video). Results show that while brain entropy increases with LSD under all of the experimental conditions, it exhibits the largest changes when subjects have their eyes closed. Furthermore, brain entropy changes are consistently associated with subjective ratings of the psychedelic experience, but this relationship is disrupted when participants are viewing a video─potentially due to a “competition” between external stimuli and endogenous LSD-induced imagery. Taken together, our findings provide strong quantitative evidence of the role of context in modulating neural dynamics during a psychedelic experience, underlining the importance of performing psychedelic psychotherapy in a suitable environment.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Murphy RJ, Godfrey K, Shaw AD, Muthukumaraswamy S, Sumner RLet al., 2024,

  Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial

  , BMC NEUROSCIENCE, Vol: 25, ISSN: 1471-2202
  • Cite
• Journal article
  Erritzoe D, Timmermann C, Godfrey K, Castro-Rodrigues P, Peill J, Carhart-Harris RL, Nutt DJ, Wall MBet al., 2024,

  Exploring mechanisms of psychedelic action using neuroimaging

  , Nature Mental Health, Vol: 2, Pages: 141-153

  Modern psychedelic research and clinical development is at a crucial inflection point, with great potential for the treatment of many mental illnesses demonstrated but significant questions that remain unresolved. Neuroimaging has been pivotal in the modern era of psychedelic research, providing crucial insights into the acute effects of these drugs that revealed translational, clinical potential. Here we review this evidence from functional magnetic resonance imaging, positron emission tomography and magnetoencephalography/electroencephalography studies and describe how these findings inform computational models of both the acute action of psychedelics and their longer-term therapeutic effects. This approach, based on multi-modal neuroimaging, provides a solid evidence base for these therapies as they move forwards, as well as a fuller understanding of the powerful effects of psychedelics on the phenomenology of human consciousness.

  • Abstract
  • Cite
  • Citations: 8
• Journal article
  Barbut Siva J, Barba T, Kettner H, Kuc J, Nutt DJ, Carhart-Harris R, Erritzoe Det al., 2024,

  Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study

  , JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 38, Pages: 145-155, ISSN: 0269-8811
  • Cite
• Journal article
  Szigeti B, Weiss B, Rosas FE, Erritzoe D, Nutt D, Carhart-Harris Ret al., 2024,

  Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression

  , PSYCHOLOGICAL MEDICINE, ISSN: 0033-2917
  • Cite
• Journal article
  James E, Erritzoe D, Benway T, Joel Z, Timmermann C, Good M, Agnorelli C, Weiss BM, Barba T, Campbell G, Jones MB, Hughes C, Topping H, Boyce M, Routledge Cet al., 2024,

  Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

  , FRONTIERS IN PSYCHIATRY, Vol: 14, ISSN: 1664-0640
  • Cite
• Journal article
  Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe Det al., 2024,

  Personality change in a trial of psilocybin therapy vs escitalopram treatment for depression

  , Psychological Medicine, Vol: 54, Pages: 178-192, ISSN: 0033-2917

  Background:Psilocybin Therapy (PT) is being increasingly studied as a psychiatric intervention. Personality relates to mental health and can be used to probe the nature of PT's therapeutic action.Methods:In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, over a core 6-week trial period. Five-Factor model personality domains, Big Five Aspect Scale Openness aspects, Absorption, and Impulsivity were measured at Baseline, Week 6, and Month 6 follow-up.Results:PT was associated with decreases in neuroticism (B = −0.63), introversion (B = −0.38), disagreeableness (B = −0.47), impulsivity (B = −0.40), and increases in absorption (B = 0.32), conscientiousness (B = 0.30), and openness (B = 0.23) at week 6, with neuroticism (B = −0.47) and disagreeableness (B = −0.41) remaining decreased at month 6. Escitalopram Treatment (ET) was associated with decreases in neuroticism (B = −0.38), disagreeableness (B = −0.26), impulsivity (B = −0.35), and increases in openness (B = 0.28) at week 6, with neuroticism (B = −0.46) remaining decreased at month 6. No significant between-condition differences were observed.Conclusions:Personality changes across both conditions were in a direction consistent with improved mental health. With the possible exception of trait absorption, there were no compelling between-condition differences warranting conclusions regarding a selective action of PT (v. ET) on personality; however, post-ET changes in personality were significantly moderated by pre-trial positive expectancy for escitalopram, whereas expectancy did not moderate response to PT.

  • Abstract
  • Cite
• Journal article
  Luan LX, Eckernas E, Ashton M, Rosas FE, Uthaug M, Bartha A, Jagger S, Gascon-Perai K, Gomes L, Nutt DJ, Erritzoe D, Carhart-Harris RL, Timmermann Cet al., 2024,

  Psychological and physiological effects of extended DMT

  , JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 38, Pages: 56-67, ISSN: 0269-8811
  • Cite
• Journal article
  Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe Det al., 2024,

  Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM.

  , Psychol Med, Vol: 54
  • Author Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.